Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and American markets, has announced the enrollment of its first patient in a Phase I clinical study for YL-17231, a novel pan-KRAS inhibitor targeting malignant solid tumors, at the MD Anderson Cancer Center.
This milestone follows a five-year partnership established between Yingli Pharma and MD Anderson in 2022, during which multiple programs have reached significant development stages.
YL-17231 is distinguished as the world’s first oral small molecule inhibitor targeting the KRAS switch II pocket. KRAS mutations are among the most prevalent genetic alterations in cancer, affecting approximately 25% of patients, with the KRAS G12C, G12D, and G12V mutations being particularly common across various tumor types. Additionally, YL-13027, which recently received approval for a Phase II combination study in the US, is concurrently undergoing Phase I clinical trials in both China and the US.- Flcube.com
